Published in Mol Imaging on February 01, 2010
High-affinity peptide against MT1-MMP for in vivo tumor imaging. J Control Release (2011) 1.59
Integrin targeting for tumor optical imaging. Theranostics (2011) 1.47
Integrin αvβ3-targeted IRDye 800CW near-infrared imaging of glioblastoma. Clin Cancer Res (2012) 0.96
Exploring new near-infrared fluorescent disulfide-based cyclic RGD peptide analogs for potential integrin-targeted optical imaging. Bioorg Med Chem Lett (2011) 0.88
Integrin targeted delivery of radiotherapeutics. Theranostics (2011) 0.88
FITC-conjugated cyclic RGD peptides as fluorescent probes for staining integrin αvβ3/αvβ5 in tumor tissues. Bioconjug Chem (2014) 0.87
Non-invasive imaging of endothelial progenitor cells in tumor neovascularization using a novel dual-modality paramagnetic/near-infrared fluorescence probe. PLoS One (2012) 0.84
Preclinical molecular imaging of tumor angiogenesis. Q J Nucl Med Mol Imaging (2010) 0.83
Characterization of chemical, radiochemical and optical properties of a dual-labeled MMP-9 targeting peptide. Bioorg Med Chem (2011) 0.82
Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab. Mol Cancer Ther (2010) 0.82
Longitudinal monitoring of tumor antiangiogenic therapy with near-infrared fluorophore-labeled agents targeted to integrin αvβ3 and vascular endothelial growth factor. Eur J Nucl Med Mol Imaging (2014) 0.79
Small molecule fluorophore and copolymer RGD peptide conjugates for ex vivo two-photon fluorescence tumor vasculature imaging. Biomaterials (2012) 0.77
GX1-conjugated poly(lactic acid) nanoparticles encapsulating Endostar for improved in vivo anticolorectal cancer treatment. Int J Nanomedicine (2015) 0.76
Noninvasive monitoring of early antiangiogenic therapy response in human nasopharyngeal carcinoma xenograft model using MRI with RGD-conjugated ultrasmall superparamagnetic iron oxide nanoparticles. Int J Nanomedicine (2016) 0.75
Molecular imaging in tumor angiogenesis and relevant drug research. Int J Biomed Imaging (2011) 0.75
A Hybrid Peptide PTS that Facilitates Transmembrane Delivery and Its Application for the Rapid In vivo Imaging via Near-Infrared Fluorescence Imaging. Front Pharmacol (2016) 0.75
Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science (1994) 12.83
Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov (2003) 6.66
Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur Radiol (2002) 6.06
Definition of two angiogenic pathways by distinct alpha v integrins. Science (1995) 6.00
Fluorescence-enhanced, near infrared diagnostic imaging with contrast agents. Curr Opin Chem Biol (2002) 3.31
Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol Rev (1998) 3.05
The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest (1999) 2.88
Optical contrast agents and imaging systems for detection and diagnosis of cancer. Int J Cancer (2008) 2.72
Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med (2006) 2.65
(64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med (2007) 2.50
In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res (2004) 2.46
Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res (2002) 2.38
Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. Magn Reson Med (2005) 2.30
Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. J Nucl Med (2004) 2.26
In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cancer Res (2006) 2.09
Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res (2007) 2.01
Near-infrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice. Bioconjug Chem (2005) 2.01
(68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression. Eur J Nucl Med Mol Imaging (2008) 1.91
Multimodality imaging of tumor integrin alphavbeta3 expression. Mini Rev Med Chem (2006) 1.70
(68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging. Eur J Nucl Med Mol Imaging (2009) 1.69
Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med Chem (2006) 1.64
Near-infrared optical imaging of integrin alphavbeta3 in human tumor xenografts. Mol Imaging (2004) 1.64
18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis and microPET imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging (2007) 1.49
Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimers. Mol Imaging Biol (2006) 1.46
[18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res (2007) 1.45
Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers. Mol Pharm (2009) 1.41
Alphavbeta3-integrin imaging: a new approach to characterise angiogenesis? Eur J Nucl Med Mol Imaging (2006) 1.39
Noninvasive imaging of tumor integrin expression using (18)F-labeled RGD dimer peptide with PEG (4) linkers. Eur J Nucl Med Mol Imaging (2009) 1.35
Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN. J Med Chem (2009) 1.26
Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. J Med Chem (2008) 1.18
Integrin alpha(v)beta(3)-Targeted Cancer Therapy. Drug Dev Res (2008) 1.17
Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme. Clin Cancer Res (2008) 1.14
In vivo imaging of integrin alpha v beta 3 expression using fluorescence-mediated tomography. Eur J Nucl Med Mol Imaging (2006) 1.08
Linker effects on biological properties of 111In-labeled DTPA conjugates of a cyclic RGDfK dimer. Bioconjug Chem (2007) 1.00
In vivo noninvasive optical imaging of receptor-mediated RGD internalization using self-quenched Cy5-labeled RAFT-c(-RGDfK-)(4). Mol Imaging (2007) 0.93
Site-specifically biotinylated VEGF(121) for near-infrared fluorescence imaging of tumor angiogenesis. Mol Pharm (2009) 0.89
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
High-thermoelectric performance of nanostructured bismuth antimony telluride bulk alloys. Science (2008) 7.34
In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol (2006) 6.93
The role of Scgb1a1+ Clara cells in the long-term maintenance and repair of lung airway, but not alveolar, epithelium. Cell Stem Cell (2009) 6.44
Carbon nanotubes as photoacoustic molecular imaging agents in living mice. Nat Nanotechnol (2008) 6.41
Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett (2006) 5.63
Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc Natl Acad Sci U S A (2008) 4.89
In vivo visualization of embryonic stem cell survival, proliferation, and migration after cardiac delivery. Circulation (2006) 4.48
Multimodality molecular imaging of tumor angiogenesis. J Nucl Med (2008) 3.99
Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res (2008) 3.47
MicroRNA-mediated control of oligodendrocyte differentiation. Neuron (2010) 3.24
US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology (2008) 3.15
microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med (2005) 2.96
Nanoparticle-based theranostic agents. Adv Drug Deliv Rev (2010) 2.86
Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J Nucl Med (2007) 2.86
Dynamic and static interactions between p120 catenin and E-cadherin regulate the stability of cell-cell adhesion. Cell (2010) 2.83
PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med (2008) 2.77
microPET-based biodistribution of quantum dots in living mice. J Nucl Med (2007) 2.76
SLIT2-mediated ROBO2 signaling restricts kidney induction to a single site. Dev Cell (2004) 2.74
Nanoplatforms for targeted molecular imaging in living subjects. Small (2007) 2.69
Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2. J Nucl Med (2006) 2.65
Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small (2009) 2.59
Neurotrophins and netrins require calcineurin/NFAT signaling to stimulate outgrowth of embryonic axons. Cell (2003) 2.54
Deletion of PIK3C3/Vps34 in sensory neurons causes rapid neurodegeneration by disrupting the endosomal but not the autophagic pathway. Proc Natl Acad Sci U S A (2010) 2.53
(64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med (2007) 2.50
PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials (2010) 2.31
Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging (2007) 2.31
The calcium-activated chloride channel anoctamin 1 acts as a heat sensor in nociceptive neurons. Nat Neurosci (2012) 2.28
PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J Nucl Med (2007) 2.28
Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma. Am J Gastroenterol (2010) 2.20
PET of vascular endothelial growth factor receptor expression. J Nucl Med (2006) 2.18
MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol (2004) 2.18
In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cancer Res (2006) 2.09
Mesothelium contributes to vascular smooth muscle and mesenchyme during lung development. Proc Natl Acad Sci U S A (2008) 2.08
Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J Clin Invest (2004) 2.06
A small peptide mimicking the key domain of MEPE/OF45 interacting with CHK1 protects human cells from radiation-induced killing. Cell Cycle (2010) 2.06
Imaging of integrins as biomarkers for tumor angiogenesis. Curr Pharm Des (2008) 2.04
Near-infrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice. Bioconjug Chem (2005) 2.01
Ultrahigh sensitivity carbon nanotube agents for photoacoustic molecular imaging in living mice. Nano Lett (2010) 2.00
Unc-51-like kinase 1/2-mediated endocytic processes regulate filopodia extension and branching of sensory axons. Proc Natl Acad Sci U S A (2007) 1.95
(68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression. Eur J Nucl Med Mol Imaging (2008) 1.91
18F-labeled galacto and PEGylated RGD dimers for PET imaging of αvβ3 integrin expression. Mol Imaging Biol (2009) 1.90
Ultrasmall c(RGDyK)-coated Fe3O4 nanoparticles and their specific targeting to integrin alpha(v)beta3-rich tumor cells. J Am Chem Soc (2008) 1.89
Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging. Nat Protoc (2008) 1.87
A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido)ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expression. J Nucl Med (2006) 1.83
How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther (2006) 1.81
Pulse accumulation, radial heat conduction, and anisotropic thermal conductivity in pump-probe transient thermoreflectance. Rev Sci Instrum (2008) 1.80
64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression. Bioconjug Chem (2007) 1.79
Unusual magnetic properties of one-dimensional molecule-based magnets associated with a structural phase transition. Inorg Chem (2002) 1.78
Near-infrared fluorescent deoxyglucose analogue for tumor optical imaging in cell culture and living mice. Bioconjug Chem (2006) 1.75
Distinct Nav1.7-dependent pain sensations require different sets of sensory and sympathetic neurons. Nat Commun (2012) 1.72
GAP production of TCM herbs in China. Planta Med (2010) 1.70
(68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging. Eur J Nucl Med Mol Imaging (2009) 1.69
Surface-engineered magnetic nanoparticle platforms for cancer imaging and therapy. Acc Chem Res (2011) 1.69
Upconversion nanoparticles: design, nanochemistry, and applications in theranostics. Chem Rev (2014) 1.68
Analyzing somatosensory axon projections with the sensory neuron-specific Advillin gene. J Neurosci (2007) 1.67
Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. Mol Biol Cell (2004) 1.67
Activation of dormant ovarian follicles to generate mature eggs. Proc Natl Acad Sci U S A (2010) 1.66
Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging (2006) 1.66
Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med Chem (2006) 1.64
Click chemistry for (18)F-labeling of RGD peptides and microPET imaging of tumor integrin alphavbeta3 expression. Bioconjug Chem (2007) 1.64
Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem Rev (2010) 1.63
DNA methylation presents distinct binding sites for human transcription factors. Elife (2013) 1.63
Why integrin as a primary target for imaging and therapy. Theranostics (2011) 1.61
High-affinity peptide against MT1-MMP for in vivo tumor imaging. J Control Release (2011) 1.59
Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels. Radiology (2011) 1.59
Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging. Stem Cells (2009) 1.58
Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug Chem (2011) 1.56
Oxorhenium(V) complexes containing tridentate Schiff-base and monothiol coligands. Inorganica Chim Acta (2000) 1.56
Mechanism for myocardial localization and rapid liver clearance of Tc-99m-N-MPO: a new perfusion radiotracer for heart imaging. J Nucl Cardiol (2009) 1.56
Light-triggered theranostics based on photosensitizer-conjugated carbon dots for simultaneous enhanced-fluorescence imaging and photodynamic therapy. Adv Mater (2012) 1.56
Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur J Nucl Med Mol Imaging (2008) 1.55
A functional synonymous coding variant in the IL1RN gene is associated with survival in septic shock. Am J Respir Crit Care Med (2014) 1.53
Mammalian target of rapamycin (mTOR) activation increases axonal growth capacity of injured peripheral nerves. J Biol Chem (2010) 1.52
Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res (2004) 1.52
Kinetic characterization of a novel cationic (99m)Tc(I)-tricarbonyl complex, (99m)Tc-15C5-PNP, for myocardial perfusion imaging. J Nucl Cardiol (2010) 1.50
Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. Nucleic Acids Res (2008) 1.49
Characterizing breast cancer xenograft epidermal growth factor receptor expression by using near-infrared optical imaging. Acta Radiol (2009) 1.49
Integrin targeting for tumor optical imaging. Theranostics (2011) 1.47
Effects of nanoparticle size on cellular uptake and liver MRI with polyvinylpyrrolidone-coated iron oxide nanoparticles. ACS Nano (2010) 1.46
microPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J Nucl Med (2007) 1.46
Near-infrared fluorescence imaging of tumor integrin alpha v beta 3 expression with Cy7-labeled RGD multimers. Mol Imaging Biol (2006) 1.46
N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma. Genes Dev (2009) 1.45
Candidate pathway-based genome-wide association studies identify novel associations of genomic variants in the complement system associated with coronary artery disease. Circ Cardiovasc Genet (2014) 1.45
SOX17 antagonizes WNT/β-catenin signaling pathway in hepatocellular carcinoma. Epigenetics (2010) 1.45
First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J Nucl Med (2013) 1.44
Long-term renal changes in the liver-specific glucokinase knockout mouse: implications for renal disease in maturity-onset diabetes of the young 2. Transl Res (2010) 1.44
Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy. Angew Chem Int Ed Engl (2009) 1.44
Photosensitizer-loaded gold vesicles with strong plasmonic coupling effect for imaging-guided photothermal/photodynamic therapy. ACS Nano (2013) 1.44
Functional genomics analysis of Singapore grouper iridovirus: complete sequence determination and proteomic analysis. J Virol (2004) 1.44